Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Research Field Neuroscience, Cell & molecular biology

A Better AD Model

Fifty million people live with dementia around the globe – approximately two thirds of which suffer from Alzheimer’s disease. Driven by an aging population, this daunting figure is expected to exceed 152 million by 2050. The potential economic impact? The World Alzheimer Report 2018 makes for a worrying read: care for dementia currently exceeds $1 trillion a year – a figure that is forecast to double by 2030 (1). The report called for significant investment in the field and, in response, the G8 countries committed to developing a dementia cure or treatment by 2025. How? By collectively increasing funding for dementia research, calling for greater innovation, and recognizing dementia as a growing threat to global health.

Despite being described over a century ago, we are only now beginning to understand the molecular mechanisms that underpin AD pathology (2). In Alzheimer’s patients, abnormal aggregates of the protein amyloid beta (Aβ) – the hallmark of the disease – can be seen at the microscopic level (3); yet, the hypothesis that amyloid accumulation is the major cause of neurodegeneration has come under increasing scrutiny. Now, evidence suggests that prefibrillar soluble Aβ oligomers are more toxic to neurons, and inhibit many important neuronal activities that relate to the symtoms of AD (4).

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!


Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Brett Spangler

Product Manager, LPB-Bioscience Solutions, Lonza, USA

Related Solutions

Research Field Drug discovery

Dental Curing Lights: Clinical Reality

| Contributed by Ocean Optics

Research Field Genetics

Measuring DNA Absorbance with the STS-UV

| Contributed by Ocean Optics

Related Articles

Disease Area Neurological

Getting on Target for Alzheimer’s

| Neil Cashman, James Kupiec

Research Field Neuroscience

Decoding Depression

| Jonathan James

Disease Area Cancer

Gurus of Brain Oncology

| Jonathan James

Most Popular

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts